Jump to content

Kenneth Ouriel

Edit links
From Wikipedia, the free encyclopedia

Kenneth Ouriel
Ouriel in 2012
Born (1956-10-21) October 21, 1956 (age 68)
Rochester, New York, US
EducationUniversity of Rochester,
University of Chicago
Columbia Business School,
London Business School
Years active28
Known forresearch; administration;
famous patients; textbooks
Medical career
ProfessionPhysician
InstitutionsCleveland Clinic,
Shaikh Khalifa Medical City,
New York-Presbyterian Hospital
Sub-specialtiesVascular surgery
ResearchVascular surgery research
AwardsLiebig Foundation Award[1]

Kenneth Ouriel (born October 21, 1956) is a vascular surgeon[2] and medical researcher. In 2007, Ouriel was appointed the chief executive officer of Sheikh Khalifa Medical City in Abu Dhabi.[3] In 2009, he was senior vice president and chief of international operations at NewYork-Presbyterian Hospital.[2] He has been described as one of America's top vascular surgeons.[1]

Early life and education

[edit]

Ouriel was born in Rochester, New York, entered college at age 16, majored in biology and psychology at the University of Rochester and belonged to the fraternity Alpha Delta Phi.[2] He was elected to Phi Beta Kappa in 1976 and graduated summa cum laude in 1977.[2] He studied medicine at the University of Chicago and graduated in 1981 with Honors.[2] He began a residency in general surgery at the University of Rochester Medical Center and completed a vascular surgical fellowship in 1987.[2] He got a National Institutes of Health grant to study thrombosis and published results from a large, multicenter randomized trial of clot busting therapy in The New England Journal of Medicine in 1998.[2]

Career

[edit]

In 1998, he was recruited to the Cleveland Clinic as the chief of Vascular Surgery. He was promoted to Chief of Surgery in 2003 where he supervised 340 surgeons in the largest surgical department in the world.[2][4] He authored three textbooks in vascular surgery[5][6][7] and over 250 original scientific articles on a wide variety of vascular surgical topics, focusing on minimally invasive means to treat vascular disease.[2]

In 2001, he treated former presidential candidate Bob Dole who, at age 77, had an abdominal aortic aneurysm; Ouriel led a team of surgeons that inserted a stent graft.[8] "Ouriel said that the team inserted a Y-shaped tube through an incision in Dole's leg and placed it inside the weakened portion of the aorta. The aneurysm will eventually contract around the stent, which will remain in place for the rest of Dole's life," wrote a reporter.[8] Ouriel was the principal investigator on a five-year $5 million National Institutes of Health grant to study intravascular ultrasound regarding atherosclerotic plaque.[2]

In June 2007, Ouriel became chief executive officer of Sheikh Khalifa Medical City in Abu Dhabi, when Cleveland Clinic and the Abu Dhabi health authority formed a partnership in which the Clinic took over[9][3] management of the health care facilities.[10] In that connection, Ouriel matriculated in an Executive MBA program in global business jointly run by Columbia Business School and the London Business School.[1] Ouriel worked on upgrade systems involving the future hospital's financial, decision-support management, inventory control and medical productivity software.[11] Ouriel was the CEO of the Sheikh Khalifa Medical City.[1][11][12] Ouriel, as part of the UAE health authority, met with visiting dignitaries, including First Lady Laura Bush.[13] Ouriel completed his master's degree in business administration from Columbia and London Business Schools.[1] While heading the Sheikh Khalifa Medical City in Abu Dhabi in the United Arab Emirates, Ouriel initiated a controversial move to disclose hospital data online which would allow people to get a "snapshot of the facility's clinical strengths and weaknesses"; he favors transparency.[14]

Ouriel facilitated the development of the first permanent renal transplantation program in the United Arab Emirates, where the Sheikh Khalifa team performed their first kidney transplant in early 2008.[2] In June 2008, Ouriel became senior vice president and chief of international operations at New York-Presbyterian.[2] In 2009, Ouriel made speeches to medical professionals about such topics as retaining patients and public-private partnerships.[15]

In 2010, Ouriel founded Syntactx, a contract medical research company that provides support for diagnostic labs, medical device and pharmaceutical companies in designing and carrying out clinical research trials, and thereafter led the company.[16] It was announced in January 2021 that Syntactx was acquired by North American Science Associates (NAMSA).[17]

Publications

[edit]
  • 1995, textbook, Lower Extremity Vascular Disease[6]
  • 1998, textbook, Mastery of Vascular and Endovascular Surgery[7]
  • 2005, textbook, Complications In Endovascular Therapy[5]
  • 1998, paper, A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS)[18]
  • 2001, paper, Peripheral arterial disease[19]
  • 2013, paper, Reporting standards for adverse events after medical device use in the peripheral vascular system[20]

References

[edit]
  1. ^ a b c d e Joanne Bladd (October 2, 2007). "Dr business". arabianbusiness.com. Retrieved November 12, 2009. ... Ouriel was .. practicing medicine for more than 15 years ... received the Liebig Foundation Award for excellence in vascular surgical research and had been regularly billed among America's top surgeons....
  2. ^ a b c d e f g h i j k l "Dr. Kenneth Ouriel (biography)". New York-Presbyterian Hospital. September 22, 2009. Retrieved September 22, 2009.
  3. ^ a b Bladd, Joanne (October 2, 2007). "Dr business: From MD to MBA; why the business of medicine is sending the region's physicians back to school for business skills". Arabian Business. Retrieved June 2, 2023.
  4. ^ DENISE GRADY (March 18, 2004). "After Unusual Fatality, Transplant Expert Revives Career". The New York Times. Retrieved September 22, 2009.
  5. ^ a b Ouriel, Kenneth (September 26, 2005). Complications In Endovascular Therapy. Informa HealthCare. pp. 472 pages. ISBN 978-0-8247-5420-4. Archived from the original on September 29, 2011. Retrieved September 23, 2009.
  6. ^ a b Ouriel, Kenneth (January 1995). Lower Extremity Vascular Disease (Hardcover) Kenneth Ouriel (editor). W.B. Saunders Company. pp. 440 pages. ISBN 978-0-7216-4749-4.
  7. ^ a b Ouriel, Kenneth; Robert B. Rutherford (January 15, 1998). Mastery of Vascular and Endovascular Surgery. W.B. Saunders Company. pp. 285 pages. ISBN 978-0-7216-6994-6.
  8. ^ a b "Bob Dole has surgery to treat aneurysm". USA Today via Associated Press. June 27, 2001. Retrieved September 22, 2009.
  9. ^ "Regional News: MIDWEST". Modern Healthcare. 37 (25): 20–21. June 18, 2007. Retrieved May 16, 2023.
  10. ^ Zicari, Peter (June 4, 2007). "Clinic to take over Abu Dhabi facilities". Cleveland Plain Dealer. Retrieved July 7, 2023.
  11. ^ a b Gregg Blesch (August 6, 2007). "Dubai and other United Arab Emirates states are using U.S. know-how to build a cutting-edge healthcare infrastructure". ModernHealthcare.com. Retrieved November 12, 2009. Ouriel has set about integrating the Cleveland Clinic's medical and administrative procedures and capabilities into the system in Abu Dhabi. His first steps have included recruiting staff from "around the world" and beginning to tackle significant technology challenges, Ouriel wrote in an e-mail responding to a recent query about how things were going so far.[dead link‍]
  12. ^ "Regional Success Stories". Kuwait Health Initiative. March 5, 2007. Archived from the original on May 28, 2009. Retrieved November 12, 2009. This conglomerate of health care facilities includes a 700-bed tertiary care facility, a 150-bed psychiatric hospital, and a 100-bed rehabilitation center. Additionally, the SKMC also controls a number of outpatient clinics and primary care facilities in Abu Dhabi. Recently, the Health Authority of Abu Dhabi delegated the management of the SKMC to the prestigious Cleveland Clinic. Dr. Ken Ouriel, the Chairman of the Department of Surgery at Cleveland Clinic, was named CEO of the SKMC
  13. ^ Hala Moddelmog (October 22, 2007). "Abu Dhabi whirlwind". Susan G. Komen for the Cure. Retrieved November 12, 2009. Since I didn't have prepared remarks (and of course, Dr. Ahmet, Dr. Ouriel, and Mrs. Bush did), I just spoke to the survivors praising their courage and telling them that Komen wouldn't stop until all women have heard the message and have access to care.
  14. ^ "SKMC goes on record with results". Arabian Business. October 17, 2007. Retrieved November 12, 2009. We want to be upfront," said CEO Dr Ken Ouriel. "How many of these operations we did, what our outcomes are with specific diseases - we want to see how we compare to certain benchmarks. We might not always be above the benchmark, but patients have a right to know.
  15. ^ "Leaders in Healthcare Conference Session 2:Future Healthcare Human Resources". Arab Health Congress. January 26, 2009. Archived from the original on April 14, 2009. Retrieved November 12, 2009. Challenges of Retaining Patients in the GCC & the Impact of Private/Public Partnerships Dr. Kenneth Ouriel, Senior Vice-President, Chief of International Operations, New York Presbyterian Hospital
  16. ^ "Graffiti artists let loose inside Four World Trade Center". WREG News. December 4, 2017. Retrieved July 6, 2023.
  17. ^ LaHucik, Kyle (August 4, 2021). "Device-focused CRO NAMSA buys Clinlogix for 3rd acquisition of 2021". Fierce Biotech. Retrieved June 2, 2023.
  18. ^ Ouriel K, Veith FJ, Sasahara AA (1998) A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 338 (16):1105-11. DOI:10.1056/NEJM199804163381603 PMID 9545358
  19. ^ Ouriel K (2001) Peripheral arterial disease. Lancet 358 (9289):1257-64. DOI:10.1016/S0140-6736(01)06351-6 PMID 11675083
  20. ^ Ouriel K, Fowl RJ, Davies MG, Forbes TL, Gambhir RP, Morales JP, et al., (2013) Reporting standards for adverse events after medical device use in the peripheral vascular system. J Vasc Surg 58 (3):776-86. DOI:10.1016/j.jvs.2013.06.059 PMID 23972246
[edit]
  • Syntactx, firm founded by Ouriel in 2010
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kenneth_Ouriel&oldid=1229857736"